Metformin as RenoProtector of Progressive Kidney Disease

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

290

Participants

Timeline

Start Date

November 5, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Chronic Kidney Diseases
Interventions
DRUG

Metformin Hydrochloride

"The intervention will consist in IMP treatment during 30 months with half of the patients treated with Metformin Glucophage SR. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.~During the first month of the trial a dose of 1x500mg will be used in order to avoid as much as possible some well-known mainly gastrointestinal side effects of metformin treatment ."

DRUG

Placebo Oral Tablet

The intervention will consist in IMP treatment during 30 months with half of the patients treated with matched placebo. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.

Trial Locations (19)

8800

AZ Delta, Roeselare

Unknown

OLVZ Aalst, Aalst

Epicura Ath, Ath

Epicura Baudour, Baudour

Imelda Ziekenhuis Bonheiden, Bonheiden

CHU Brugmann, Brussels

Hôpital Erasme, Brussels

UZ Brussel, Brussels

Grand Hôpital de Charleroi, Charleroi

Antwerp University Hospital, Edegem

Ghent University Hospital, Ghent

Jessa Ziekenhuis, Hasselt

Centre Hospitalier Régional de la Citadelle, Liège

Centre Hospitalier Universitaire Liège (CHU Liège), Liège

Centre Hospitalier Régional de Namur, Namur

AZ Nikolaas, Sint-Niklaas

Centre Hospitalier de Wallonie Picarde, Tournai

AZ Turnhout, Turnhout

CHR Verviers, Verviers

All Listed Sponsors
collaborator

University Hospital, Antwerp

OTHER

lead

Universiteit Antwerpen

OTHER